PMC:7534795 / 20046-20195 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T96290","span":{"begin":65,"end":73},"obj":"Body_part"},{"id":"T24819","span":{"begin":112,"end":117},"obj":"Body_part"}],"attributes":[{"id":"A75019","pred":"fma_id","subj":"T96290","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A40022","pred":"fma_id","subj":"T24819","obj":"http://purl.org/sig/ont/fma/fma67498"}],"text":"• Tocilizumab may be a promising investigative therapy to reduce cytokine release syndrome and associated multi-organ damage (ChiCTR2000029765, 2020)"}

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T40","span":{"begin":112,"end":117},"obj":"Body_part"}],"attributes":[{"id":"A40","pred":"uberon_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"• Tocilizumab may be a promising investigative therapy to reduce cytokine release syndrome and associated multi-organ damage (ChiCTR2000029765, 2020)"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T58937","span":{"begin":21,"end":22},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T90672","span":{"begin":112,"end":117},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"}],"text":"• Tocilizumab may be a promising investigative therapy to reduce cytokine release syndrome and associated multi-organ damage (ChiCTR2000029765, 2020)"}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T125","span":{"begin":0,"end":149},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• Tocilizumab may be a promising investigative therapy to reduce cytokine release syndrome and associated multi-organ damage (ChiCTR2000029765, 2020)"}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T86","span":{"begin":65,"end":90},"obj":"Phenotype"}],"attributes":[{"id":"A86","pred":"hp_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"• Tocilizumab may be a promising investigative therapy to reduce cytokine release syndrome and associated multi-organ damage (ChiCTR2000029765, 2020)"}